NCT00811785View on ClinicalTrials.gov

Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

February 27, 2009

Primary Completion Date

August 28, 2020

Study Completion Date

August 28, 2020

Conditions
Menkes DiseaseOccipital Horn SyndromeUnexplained Copper Deficiency
Interventions
DRUG

Copper Histidine

Daily subcutaneous injections for three years

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors
All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Cyprium Therapeutics, Inc.

INDUSTRY